Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
Due to the low incidence of rare EGFR mutation, its response to EGFR-TKI has not been fully investigated. L747P is a rare EGFR mutation in EGFR exon 19. Previous case reports showed that patients with EGFR L747P mutation responded to afatinib treatment. However, we encountered a patient with EGFR L7...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.863771/full |
| _version_ | 1811345023256494080 |
|---|---|
| author | Yibin Li Weixi Guo Bin Jiang Chengkun Han Feng Ye Jingxun Wu |
| author_facet | Yibin Li Weixi Guo Bin Jiang Chengkun Han Feng Ye Jingxun Wu |
| author_sort | Yibin Li |
| collection | DOAJ |
| description | Due to the low incidence of rare EGFR mutation, its response to EGFR-TKI has not been fully investigated. L747P is a rare EGFR mutation in EGFR exon 19. Previous case reports showed that patients with EGFR L747P mutation responded to afatinib treatment. However, we encountered a patient with EGFR L747P who was resistant to afatinib but responded to dacomitinib. It is the first case report of the effective application of dacomitinib in a patient with L747P mutation and BMS, and the efficacy of BMS achieved PR. |
| first_indexed | 2024-04-13T19:56:52Z |
| format | Article |
| id | doaj.art-e2e48286ba914a7c8dfd2ede280de3cb |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T19:56:52Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-e2e48286ba914a7c8dfd2ede280de3cb2022-12-22T02:32:18ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.863771863771Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastasesYibin Li0Weixi Guo1Bin Jiang2Chengkun Han3Feng Ye4Jingxun Wu5Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, ChinaDepartment of Thoracic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, ChinaDepartment of Neurology, The First Affiliated Hospital of Xiamen University, Xiamen, ChinaDepartment of Radiology, The First Affiliated Hospital of Xiamen University, Xiamen, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, ChinaDue to the low incidence of rare EGFR mutation, its response to EGFR-TKI has not been fully investigated. L747P is a rare EGFR mutation in EGFR exon 19. Previous case reports showed that patients with EGFR L747P mutation responded to afatinib treatment. However, we encountered a patient with EGFR L747P who was resistant to afatinib but responded to dacomitinib. It is the first case report of the effective application of dacomitinib in a patient with L747P mutation and BMS, and the efficacy of BMS achieved PR.https://www.frontiersin.org/articles/10.3389/fonc.2022.863771/fullDacomitinib (PubMed CID: 11511120)lung cancerbrain metastasisEGFRL747P mutation |
| spellingShingle | Yibin Li Weixi Guo Bin Jiang Chengkun Han Feng Ye Jingxun Wu Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases Frontiers in Oncology Dacomitinib (PubMed CID: 11511120) lung cancer brain metastasis EGFR L747P mutation |
| title | Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases |
| title_full | Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases |
| title_fullStr | Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases |
| title_full_unstemmed | Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases |
| title_short | Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases |
| title_sort | case report dacomitinib is effective in lung adenocarcinoma with rare egfr mutation l747p and brain metastases |
| topic | Dacomitinib (PubMed CID: 11511120) lung cancer brain metastasis EGFR L747P mutation |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.863771/full |
| work_keys_str_mv | AT yibinli casereportdacomitinibiseffectiveinlungadenocarcinomawithrareegfrmutationl747pandbrainmetastases AT weixiguo casereportdacomitinibiseffectiveinlungadenocarcinomawithrareegfrmutationl747pandbrainmetastases AT binjiang casereportdacomitinibiseffectiveinlungadenocarcinomawithrareegfrmutationl747pandbrainmetastases AT chengkunhan casereportdacomitinibiseffectiveinlungadenocarcinomawithrareegfrmutationl747pandbrainmetastases AT fengye casereportdacomitinibiseffectiveinlungadenocarcinomawithrareegfrmutationl747pandbrainmetastases AT jingxunwu casereportdacomitinibiseffectiveinlungadenocarcinomawithrareegfrmutationl747pandbrainmetastases |